Low potency inhibition of NaV1.7 by externally applied QX-314 via a depolarizing shift in the voltage-dependence of activation

Eur J Pharmacol. 2022 Jun 15:925:175013. doi: 10.1016/j.ejphar.2022.175013. Epub 2022 May 7.

Abstract

QX-314 is a quaternary permanently charged lidocaine derivative that inhibits voltage-gated sodium channels (NaV). As it is membrane impermeable, it is generally considered that QX-314 applied externally is inactive, unless it can gain access to the internal local anesthetic binding site via another entry pathway. Here, we characterized the electrophysiological effects of QX-314 on NaV1.7 heterologously expressed in HEK293 cells, and found that at high concentrations, external QX-314 inhibited NaV1.7 current (IC50 2.0 ± 0.3 mM) and shifted the voltage-dependence to more depolarized potentials (ΔV50 +10.6 mV). Unlike lidocaine, the activity of external QX-314 was not state- or use-dependent. The effect of externally applied QX-314 on NaV1.7 channel biophysics differed to that of internally applied QX-314, suggesting QX-314 has an additional externally accessible site of action. In line with this hypothesis, disruption of the local anesthetic binding site in a [F1748A]NaV1.7 mutant reduced the potency of lidocaine by 40-fold, but had no effect on the potency or activity of externally applied QX-314. Therefore, we conclude, using an expression system where QX-314 was unable to cross the membrane, that externally applied QX-314 is able to inhibit NaV1.7 peak current at low millimolar concentrations.

Keywords: Lidocaine; Local anesthetic; Na(V)1.7; Pain; QX-314; Voltage-gated sodium channel.

MeSH terms

  • Anesthetics, Local* / pharmacology
  • HEK293 Cells
  • Humans
  • Lidocaine* / analogs & derivatives
  • Lidocaine* / pharmacology
  • Sodium / metabolism
  • Sodium Channel Blockers / pharmacology

Substances

  • Anesthetics, Local
  • Sodium Channel Blockers
  • QX-314
  • Lidocaine
  • Sodium